Company Overview and News
It has been about a month since the last earnings report for Mack-Cali Realty (CLI - Free Report) . Shares have added about 13.6% in that time frame, outperforming the S&P 500.
Mack-Cali Realty Corporation (CLI - Free Report) was a big mover last session, as the company saw its shares rise more than 6% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. The stock picked up sharply from the near-flat trend of $19.07 to $19.81 in the past one month time frame.
Outfront Media, Inc. (OUT - Free Report) reported second-quarter 2018 adjusted funds from operations (FFO) per share of 55 cents, missing the Zacks Consensus Estimate of 57 cents. Further, the figure came in lower than the year-ago tally of 56 cents. The company’s results reflect lower transit and other revenues resulting from dreary environment in national advertising. Further, the revenue figure missed the Consensus mark.
GD CUZ HIW ZTO CLI OUT
Lamar Advertising Company (LAMR - Free Report) reported second-quarter 2018 adjusted funds from operations (FFO) of $1.52 per share, marking a 9.4% increase from the year-ago tally of $1.39 per share. Results were primarily driven by growth in revenues. Same-unit digital revenues increased 6.3% during the quarter. Net revenues for the quarter climbed 5.7% from the prior-year quarter to $419.8 million.
GD CUZ HIW ZTO CLI
Shares of Mack-Cali Realty Corp (CLI - Free Report) lost nearly 2.8% in the succeeding day following the release of its second-quarter results. Investors were discouraged by a 22.2% year-over-year decline in the company’s reported revenues of $126.6 million. Further, the figure missed the Zacks Consensus Estimate of $131 million. Mack-Cali’s core funds from operations (FFO) per share of 45 cents came in lower than the year-ago figure of 60 cents.
CXW MDQZZ MGP CLI MRT
Table of Contents
Table of Contents
Investors in Mack-Cali Realty Corporation (CLI - Free Report) need to pay close attention to the stock based on moves in the options market lately. That is because the Jul 20, 2018 $17.50 Call had some of the highest implied volatility of all equity options today.
OCUL JAKK FTRPR CLI FTR
16h - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
17h - Asif
Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...
19h - Asif
Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...
Silicon Investor Message Boards
This table lists all message boards related to CLI / Mack-Cali Realty Corp. on message board site Silicon Investor.
as of ET